Margaret Olinger - 06 Jan 2022 Form 3 Insider Report for Amylyx Pharmaceuticals, Inc. (AMLX)

Role: Chief Commercial Officer
Signature: /s/ Joshua B. Cohen, as Attorney-in-Fact for Margaret Olinger
Issuer symbol: AMLX
Transactions as of: 06 Jan 2022
Net transactions value: $0
Form type: 3
Filing time: 06 Jan 2022, 16:07:47 UTC
Next filing: 10 Jan 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	AMLX	Common Stock						181,583	06 Jan 2022	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	AMLX	Stock Option (Right to Buy)							06 Jan 2022	Common Stock	89,577	$0.3700	Direct	F1
holding	AMLX	Stock Option (Right to Buy)							06 Jan 2022	Common Stock	65,000	$6.88	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	As of the date of this filing, 41,157 shares subject to such option vest and become exercisable in substantially equal monthly installments until May 13, 2023, and 48,420 shares subject to such option vest and become exercisable in substantially equal monthly installments until August 13, 2023.
F2	16,256 shares subject to such stock option shall vest on February 19, 2022 and the remainder of shares vest in monthly installments of 1,354 shares thereafter.